CommercialCoverageMedium impact
08.02.32a, Afamitresgene autoleucel (Tecelra®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
A new commercial policy for Afamitresgene autoleucel (Tecelra®), a specialized pharmacy medication, has been updated. This policy becomes effective April 1, 2025 and likely affects coverage criteria, billing requirements, or prior authorization for this specific drug therapy.
Action Required
By April 1, 2025: Billing team must review the full policy details at the provided URL to understand specific coverage criteria and billing requirements for Afamitresgene autoleucel (Tecelra®). Update prior authorization workflows and billing procedures as specified in the complete policy. Contact pharmacy benefits team to clarify any new documentation requirements.